Article
CMS finalizes narrow coverage for Aduhelm, unveils second pathway for broader access to Alzheimer's drug
Rating:
0.0
Views:
73
Likes:
1
Library:
1
Despite heavyweight lobbying, CMS stuck to its narrow national coverage determination for a controversial class of Alzheimer's disease drugs.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value